Comparative Benchmarking
In the context of the broader market, RADX competes directly with industry leaders such as DCGO and BDSX. With a market capitalization of $58.72M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of N/A stands against DCGO's 19.99% and BDSX's 81.14%. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.
